Protocol 19-288: A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Stage II - III mismatch repair deficient or microsatellite instability high rectal adenocarcinoma eligible to receive neoadjuvant therapy as standard practice.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Central Park Medical Oncology
Eastchester Cancer Center
Port Jefferson Medical Oncology
Contact us today to request an appointment.Virtual & Telemedicine available.
Learn more news and information related to COVID-19.